

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/086104 A1(51) International Patent Classification⁷: A23L 1/00,
A23P 1/04

(21) International Application Number: PCT/CA03/00520

(22) International Filing Date: 8 April 2003 (08.04.2003)


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/120,621 11 April 2002 (11.04.2002) US(71) Applicant: OCEAN NUTRITION CANADA LTD.
[CA/CA]; 1721 Lower Water Street, Halifax, Nova Scotia
B3J 1S5 (CA).(72) Inventor: YAN, Nianxi; 28 Lancaster Drive, Halifax,
Nova Scotia B3S 1E7 (CA).(74) Agents: SCHWARTZ, David, E. et al.; Smart & Biggar,
P.O. Box 2999, Station D, 900 - 55 Metcalfe Street, Ottawa,
Ontario K1P 5Y6 (CA).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(54) Title: ENCAPSULATED AGGLOMERATION OF MICROCAPSULES AND METHOD FOR THE PREPARATION
THEREOF

(57) Abstract: Microcapsules comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell, may be prepared by providing an aqueous mixture of a loading substance and a shell material, adjusting pH, temperature, concentration and/or mixing speed to form primary shells of shell material around the loading substance and cooling the aqueous mixture until the primary shells agglomerate and an outer shell of shell material forms around the agglomeration. Such microcapsules are useful for storing a substance and for delivering the substance to a desired environment.

REST-AVAILABLE COPY

WO 03/086104 A1

**ENCAPSULATED AGGLOMERATION OF MICROCAPSULES AND METHOD FOR
THE PREPARATION THEREOF**

Field of the Invention

This invention relates to microcapsules, methods
5 of preparing microcapsules and to their use.

Background of the Invention

Microcapsules are defined as small particles of
solids, or droplets of liquids, inside a thin coating of a
shell material such as beeswax, starch, gelatine or
10 polyacrylic acid. They are used, for example, to prepare
liquids as free-flowing powders or compressed solids, to
separate reactive materials, to reduce toxicity, to protect
against oxidation and/or to control the rate of release of a
substance such as an enzyme, a flavour, a nutrient, a drug,
15 etc.

Over the past fifty years, the prior art has
concentrated on so-called "single-core" microcapsules.
However, one of the problems with single-core microcapsules
is their susceptibility to rupture. To increase the
20 strength of microcapsules, it is known in the art to
increase the thickness of the microcapsule wall. However,
this leads to a reduction in the loading capacity of the
microcapsule. Another approach has been to create so-called
"multi-core" microcapsules. For example, United States
25 patent 5,780,056 discloses a "multi-core" microcapsule
having gelatine as a shell material. These microcapsules
are formed by spray cooling an aqueous emulsion of oil or
carotenoid particles such that the gelatine hardens around
"cores" of the oil or carotenoid particles. Yoshida et al.
30 (Chemical Abstract 1990:140735 or Japanese patent
publication JP 01-148338 published June 9, 1989) discloses a

complex coacervation process for the manufacture of microcapsules in which an emulsion of gelatine and paraffin wax is added to an arabic rubber solution and then mixed with a surfactant to form "multi-core" microcapsules.

- 5 Ijichi et al. (*J. Chem. Eng. Jpn.* (1997) 30(5):793-798) microencapsulated large droplets of biphenyl using a complex coacervation process to form multi-layered microcapsules. United States patents 4,219,439 and 4,222,891 disclose "multi-nucleus", oil-containing microcapsules
- 10 having an average diameter of 3-20 μm with an oil droplet size of 1-10 μm for use in pressure-sensitive copying papers and heat sensitive recording papers. While some improvement in the strength of microcapsules may be realized by using methods such as these, there remains a need for
- 15 microcapsules having good rupture strength and good oxidative barrier to the encapsulated substance, preferably in conjunction with high load volumes. Illustrative of this need is the current lack of commercially available 'multicore' microcapsules.

20 Summary of the Invention

There is provided a microcapsule comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell.

- 25 There is further provided a process for preparing microcapsules, the process comprising:

- (a) providing an aqueous mixture of a loading substance, a first polymer component of shell material and a second polymer component of shell material;
- 30 (b) adjusting pH, temperature, concentration, mixing speed or a combination thereof to form shell material

comprising the first and second polymer components, the shell material forming primary shells around the loading substance;

(c) cooling the aqueous mixture to a temperature above
5 gel point of the shell material until the primary shells form agglomerations; and,

(d) further cooling the aqueous mixture to form an outer shell of shell material around the agglomerations.

There is still further provided a process for
10 preparing microcapsules, the process comprising:

(a) providing an aqueous mixture of a first polymer component of shell material;

(b) dispersing a loading substance into the aqueous mixture;

15 (c) then adding a second polymer component of shell material to the aqueous mixture;

(d) adjusting pH, temperature, concentration, mixing speed or a combination thereof to form shell material comprising the first and second polymer components, the
20 shell material forming primary shells around the loading substance;

(e) cooling the aqueous mixture to a temperature above gel point of the shell material until the primary shells form agglomerations; and,

25 (f) further cooling the aqueous mixture to form an outer shell of shell material around the agglomerations.

Microcapsules of the present invention may be used to contain a loading substance for a variety of applications.

Brief Description of the Drawings

5 Figure 1 is an optical micrograph (400 X) of encapsulated agglomerations of microcapsules in accordance with the invention.

 Figure 2 is a second optical micrograph (400 X) of encapsulated agglomerations of microcapsules in accordance
10 with the invention.

Detailed Description

Composition:

 The loading substance may be virtually any substance that is not entirely soluble in the aqueous
15 mixture. Preferably, the loading substance is a solid, a hydrophobic liquid, or a mixture of a solid and a hydrophobic liquid. The loading substance is more preferably a hydrophobic liquid, such as grease, oil or a mixture thereof. Typical oils may be fish oils, vegetable
20 oils, mineral oils, derivatives thereof or mixtures thereof. The loading substance may comprise a purified or partially purified oily substance such as a fatty acid, a triglyceride or a mixture thereof. Omega-3 fatty acids, such as
 α -linolenic acid (18:3n3), octadecatetraenoic acid (18:4n3),
25 eicosapentaenoic acid (20:5n3) (EPA) and docosahexaenoic acid (22:6n3) (DHA), and derivatives thereof and mixtures thereof, are preferred. Many types of derivatives are well known to one skilled in the art. Examples of suitable
30 derivatives are esters, such as phytosterol esters, branched or unbranched C₁-C₃₀ alkyl esters, branched or unbranched

C₂-C₃₀ alkenyl esters or branched or unbranched C₃-C₃₀ cycloalkyl esters, in particular phytosterol esters and C₁-C₆ alkyl esters. Preferred sources of oils are oils derived from aquatic organisms (e.g. anchovies, capelin, Atlantic
5 cod, Atlantic herring, Atlantic mackerel, Atlantic menhaden, salmonids, sardines, shark, tuna, etc) and plants (e.g. flax, vegetables, algae, etc). While the loading substance may or may not be a biologically active substance, the microcapsules of the present invention are particularly
10 suited for biologically active substances, for example, drugs, nutritional supplements, flavours or mixtures thereof. Particularly preferred loading substances include antioxidants, such as CoQ₁₀ and vitamin E.

The shell material may be any material that can
15 form a microcapsule around the loading substance of interest. The shell material typically comprises at least one polymer component. Examples of polymer components include, but are not limited to, gelatines, polyphosphate, polysaccharides and mixtures thereof. Preferred polymer
20 components are gelatine A, gelatine B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, carboxymethylcellulose (CMC) or a mixture thereof. A particularly preferred form of gelatine type A has a Bloom strength of 50-350, more preferably a Bloom strength of 275.

25 The shell material is preferably a two-component system made from a mixture of different types of polymer components. More preferably, the shell material is a complex coacervate between two or more polymer components. Component A is preferably gelatine type A, although other
30 polymers are also contemplated as component A. Component B is preferably gelatine type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, carboxymethylcellulose or a mixture thereof. The molar ratio of

component A:component B that is used depends on the type of components but is typically from 1:5 to 15:1. For example, when gelatine type A and polyphosphate are used as components A and B respectively, the molar ratio of component A:component B is preferably 8:1 to 12:1; when gelatine type A and gelatine type B are used as components A and B respectively, the molar ratio of component A:component B is preferably 2:1 to 1:2; and when gelatine type A and alginate are used as components A and B respectively, the molar ratio of component A:component B is preferably 3:1 to 8:1.

Processing aids may be included in the shell material. Processing aids may be used for a variety of reasons. For example, they may be used to promote agglomeration of the primary microcapsules, control microcapsule size and/or to act as an antioxidant. Antioxidant properties are useful both during the process (e.g. during coacervation and/or spray drying) and in the microcapsules after they are formed (i.e. to extend shelf-life, etc). Preferably a small number of processing aids that perform a large number of functions is used. For example, ascorbic acid or a salt thereof may be used to promote agglomeration of the primary microcapsules, to control microcapsule size and to act as an antioxidant. The ascorbic acid or salt thereof is preferably used in an amount of about 100 ppm to about 12,000 ppm, more preferably about 1000 ppm to about 5000 ppm. A salt of ascorbic acid, such as sodium or potassium ascorbate, is particularly preferred in this capacity.

The structure of encapsulated agglomerations of microcapsules in accordance with the present invention may be seen in Figures 1 and 2, which show that smaller (primary) microcapsules have agglomerated together and that

the agglomeration is surrounded by shell material to form a larger microcapsule. Each individual primary microcapsule has its own distinct shell called the primary shell.

Furthermore, any space that there may be between the smaller
5 microcapsules is filled with more shell material to hold and surround the smaller microcapsules thereby providing an extremely strong outer shell of the larger microcapsule in addition to the primary shell that forms the smaller microcapsules within the larger microcapsule. In one sense,
10 the encapsulated agglomeration of microcapsules may be viewed as an agglomeration of walled bubbles suspended in a matrix of shell material, i.e. a "foam-like" structure. Such an encapsulated agglomeration of microcapsules provides a stronger, more rupture-resistant structure than is
15 previously known in the art, in conjunction with achieving high loads of loading substance.

The primary microcapsules (primary shells) typically have an average diameter of about 40 nm to about 10 μm , more particularly from about 0.1 μm to about 5 μm ,
20 even more particularly about 1 μm . The encapsulated agglomerations (outer shells) may have an average diameter of from about 1 μm to about 2000 μm , more typically from about 20 μm to about 1000 μm , more particularly from about 20 μm to about 100 μm , even more particularly from about 50
25 μm to about 100 μm .

The encapsulated agglomerations of microcapsules prepared by a process of the present invention typically have a combination of payload and structural strength that are better than multi-core microcapsules of the prior art.
30 For example, payloads of loading substance can be as high as about 70% by weight in microcapsules of the present invention having an average size of about 50 μm for the

outer shells and an average size of about 1 μm for the primary shells.

Process:

In the process for preparing microcapsules, an aqueous mixture of a loading substance, a first polymer component of the shell material and a second polymer component of the shell material is formed. The aqueous mixture may be a mechanical mixture, a suspension or an emulsion. When a liquid loading material is used, particularly a hydrophobic liquid, the aqueous mixture is preferably an emulsion of the loading material and the polymer components.

In a more preferred aspect, a first polymer component is provided in aqueous solution, preferably together with processing aids, such as antioxidants. A loading substance may then be dispersed into the aqueous mixture, for example, by using a homogenizer. If the loading substance is a hydrophobic liquid, an emulsion is formed in which a fraction of the first polymer component begins to deposit around individual droplets of loading substance to begin the formation of primary shells. If the loading substance is a solid particle, a suspension is formed in which a fraction of the first polymer component begins to deposit around individual particles to begin the formation of primary shells. At this point, another aqueous solution of a second polymer component may be added to the aqueous mixture.

Droplets or particles of the loading substance in the aqueous mixture preferably have an average diameter of less than 100 μm , more preferably less than 50 μm , even more preferably less than 25 μm . Droplets or particles of the

loading substance having an average diameter less than 10 μm or less than 5 μm or less than 3 μm or less than 1 μm may be used. Particle size may be measured using any typical equipment known in the art, for example, a Coulter™ LS230
5 Particle Size Analyzer, Miami, Florida, USA.

The amount of the polymer components of the shell material provided in the aqueous mixture is typically sufficient to form both the primary shells and the outer shells of the encapsulated agglomeration of microcapsules.
10 Preferably, the loading substance is provided in an amount of from about 1% to about 15% by weight of the aqueous mixture, more preferably from about 3% to about 8% by weight, and even more preferably about 6% by weight.

The pH, temperature, concentration, mixing speed
15 or a combination thereof is then adjusted to accelerate the formation of the primary shells around the droplets or particles of the loading substance. If there is more than one type of polymer component, complex coacervation will occur between the components to form a coacervate, which
20 further deposits around the loading substance to form primary shells of shell material. The pH adjustment depends on the type of shell material to be formed. For example, when gelatine type A is a polymer component, the pH may be adjusted to a value from 3.5-5.0, preferably from 4.0-5.0.
25 If the pH of the mixture starts in the desired range, then little or no pH adjustment is required. The initial temperature of the aqueous mixture is preferably set to a value of from about 40°C to about 60°C, more preferably at about 50°C. Mixing is preferably adjusted so that there is
30 good mixing without breaking the microcapsules as they form. Particular mixing parameters depend on the type of equipment being used. Any of a variety of types of mixing equipment

known in the art may be used. Particularly useful is an axial flow impeller, such as Lightnin™ A310 or A510.

The aqueous mixture may then be cooled under controlled cooling rate and mixing parameters to permit
5 agglomeration of the primary shells to form encapsulated agglomerations of primary shells. The encapsulated agglomerations are discrete particles themselves. It is advantageous to control the formation of the encapsulated agglomerations at a temperature above the gel point of the
10 shell material, and to let excess shell material form a thicker outer shell. It is also possible at this stage to add more polymer components, either of the same kind or a different kind, in order to thicken the outer shell and/or produce microcapsules having primary and outer shells of
15 different composition. The temperature is preferably lowered at a rate of 1°C/10 minutes until it reaches a temperature of from about 5°C to about 10°C, preferably about 5°C. The outer shell encapsulates the agglomeration of primary shells to form a rigid encapsulated agglomeration of
20 microcapsules.

At this stage, a cross-linker may be added to further increase the rigidity of the microcapsules by cross-linking the shell material in both the outer and primary shells and to make the shells insoluble in both aqueous and
25 oily media. Any suitable cross-linker may be used and the choice of cross-linker depends somewhat on the choice of shell material. Preferred cross-linkers are enzymatic cross-linkers (e.g. transglutaminase), aldehydes (e.g. formaldehyde or gluteraldehyde), tannic acid, alum or a
30 mixture thereof. When the microcapsules are to be used to deliver a biologically active substance to an organism, the cross-linkers are preferably non-toxic or of sufficiently low toxicity. The amount of cross-linker used depends on

the type of shell material and may be adjusted to provide more or less structural rigidity as desired. For example, when gelatine type A is used in the shell material, the cross-linker may be conveniently used in an amount of about 1.0% to about 5.0%, preferably about 2.5%, by weight of the gelatine type A. In general, one skilled in the art may routinely determine the desired amount in any given case by simple experimentation.

Finally, the microcapsules may be washed with water and/or dried to provide a free-flowing powder. Drying may be accomplished by a number of methods known in the art, such as freeze drying, drying with ethanol or spray drying. Spray drying is a particularly preferred method for drying the microcapsules. Spray drying techniques are disclosed in "Spray Drying Handbook", K. Masters, 5th edition, Longman Scientific Technical UK, 1991, the disclosure of which is hereby incorporated by reference.

Uses:

The microcapsules produced by the process of the present invention may be used to prepare liquids as free-flowing powders or compressed solids, to store a substance, to separate reactive substances, to reduce toxicity of a substance, to protect a substance against oxidation, to deliver a substance to a specified environment and/or to control the rate of release of a substance. In particular, the microcapsules may be used to deliver a biologically active substance to an organism for nutritional or medical purposes. The biologically active substance may be, for example, a nutritional supplement, a flavour, a drug and/or an enzyme. The organism is preferably a mammal, more preferably a human. Microcapsules containing the biologically active substance may be included, for example,

in foods or beverages or in drug delivery systems. Use of the microcapsules of the present invention for formulating a nutritional supplement into human food is particularly preferred.

5 Microcapsules of the present invention have good rupture strength to help reduce or prevent breaking of the microcapsules during incorporation into food or other formulations. Furthermore, the microcapsule's shells are insoluble in both aqueous and oily media, and help reduce or
.0 prevent oxidation and/or deterioration of the loading substance during preparation of the microcapsules, during long-term storage, and/or during incorporation of the microcapsules into a formulation vehicle, for example, into
.5 foods, beverages, nutraceutical formulations or pharmaceutical formulations.

Examples

Example 1:

54.5 grams gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 600 grams of deionized
20 water containing 0.5% sodium ascorbate under agitation at 50°C until completely dissolved. 5.45 grams of sodium polyphosphate was dissolved in 104 grams of deionized water containing 0.5% sodium ascorbate. 90 grams of a fish oil concentrate containing 30% eicosapentaenoic acid ethyl ester
25 (EPA) and 20% docosahexaenoic acid ethyl ester (DHA) (available from Ocean Nutrition Canada Ltd.) was dispersed with 1.0% of an antioxidant (blend of natural flavour, tocopherols and citric acid available as Duralox™ from Kalsec™) into the gelatine solution with a high speed
30 Polytron™ homogenizer. An oil-in-water emulsion was formed. The oil droplet size had a narrow distribution with an

average size of about 1 μm measured by Coulter™ LS230 Particle Size Analyzer. The emulsion was diluted with 700 grams of deionized water containing 0.5% sodium ascorbate at 50°C. The sodium polyphosphate solution was then added into the emulsion and mixed with a Lightnin™ agitator at 600 rpm. The pH was then adjusted to 4.5 with a 10% aqueous acetic acid solution. During pH adjustment and the cooling step that followed pH adjustment, a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules. Cooling was carried out to above the gel point of the gelatine and polyphosphate and the primary microcapsules started to agglomerate to form lumps under agitation. Upon further cooling of the mixture, polymer remaining in the aqueous phase further coated the lumps of primary microcapsules to form an encapsulated agglomeration of microcapsules having an outer shell and having an average size of 50 μm . Once the temperature had been cooled to 5°C, 2.7 grams of 50% gluteraldehyde was added into the mixture to further strengthen the shell. The mixture was then warmed to room temperature and kept stirring for 12 hours. Finally, the microcapsule suspension was washed with water. The washed suspension was then spray dried to obtain a free-flowing powder. A payload of 60% was obtained.

Example 2:

Encapsulated agglomerations of microcapsules were formed in accordance with the method of Example 1 except that 0.25% sodium ascorbate was used. A payload of 60% was obtained.

Example 3:

Encapsulated agglomerations of microcapsules were formed in accordance with the method of Example 1 except that no ascorbate was used. A payload of 60% was obtained.

5 Example 4:

Encapsulated agglomerations of microcapsules were formed in accordance with the method of Example 1 except that 105 grams of fish oil concentrate was used and a payload of 70% was obtained.

10 Example 5:

Encapsulated agglomerations of microcapsules were formed in accordance with the method of Example 1 except that it was applied to triglyceride (TG) fish oil (available from Ocean Nutrition Canada Ltd.) rather than ethyl ester
15 fish oil.

Example 6:

Encapsulated agglomerations of microcapsules were formed in accordance with the method of Example 1 except that gelatine (type A) and gum arabic were used as polymer
20 components of the shell material.

Example 7:

Encapsulated agglomerations of microcapsules were formed in accordance with the method of Example 1 except that 150 Bloom gelatine (type A) and polyphosphate were used
25 as polymer components of the shell material and 105 grams of fish oil concentrate was used to obtain a payload of 70%.

Example 8:

Encapsulated agglomerations of microcapsules were formed in accordance with the method of Example 1 except that transglutaminase was used to cross-link the shell material.

Example 9: Evaluation of microcapsules

The microcapsules of Examples 1-8 were evaluated for mechanical strength, encapsulated oil quality and oxidative stability.

Microcapsule shell strength was evaluated by centrifuging a given amount of the prepared microcapsule powders from each of the Examples 1-8 at 34,541 g at 25°C for 30 minutes in a Sorvall™ Super T-21 centrifuge. The original and the centrifuged powders were washed with hexane to extract oil released from the microcapsules due to shell breakage under centrifuge force. The ratio of percent free oil of the centrifuged powders to that of the original powders is used as an indicator of the shell strength. The lower the ratio, the stronger is the microcapsule's shell.

Oil quality in microcapsules was evaluated by crushing the shells of the prepared microcapsule powders from each of Examples 1-8 with a grinder. The encapsulated oil was then extracted with hexane. Peroxide Value (PV) was analyzed with American Oil Chemist Society Method (AOCS Official Method Cd 8-53: Peroxide value). A high PV indicates a higher concentration of primary oxidation products in the encapsulated oil.

Accelerated oxidative stability was evaluated by placing the prepared microcapsule powders from each of Examples 1-8 in an oxygen bomb (Oxipres™, MIKROLAB AARHUS

A/S, Denmark) with an initial oxygen pressure of 5 bar at a constant temperature of 65°C. When the encapsulated fish oil started to oxidize, the oxygen pressure dropped. The time at which the oxygen pressure started to drop is called

5 Induction Period. A longer Induction Period means that the contents of the microcapsules are better protected towards oxidation.

Results are shown in Table 1. The results indicate that the agglomerated microcapsules prepared in

10 accordance with the present invention have excellent strength and resistance to oxidation of the encapsulated loading substance.

Table 1

run #	load (%)	ascorbate (%)	Induction period (hr)	PV value	free oil ratio	notes
1	60	0.50	38	3.0	2.0	
2	60	0.25	34	4.1	1.5	
3	60	0.0	26	7.8	1.5	
4	70	0.50	38	3.2	1.7	
5	60	0.50	37	0.28	3.0	TG oil
6	60	0.50	30	3.4	1.5	gum arabic
7	70	0.50	38	4.4	2.2	150 bloom gelatin
8	60	0.50	33	3.2	1.1	enzymatic cross linking

15 Other advantages which are obvious and which are inherent to the invention will be evident to one skilled in the art. It will be understood that certain features and sub-combinations are of utility and may be employed without

reference to other features and sub-combinations. This is contemplated by and is within the scope of the claims.

Since many possible embodiments may be made of the invention without departing from the scope thereof, it is to be

5 understood that all matter herein set forth or shown in the accompanying drawings is to be interpreted as illustrative and not in a limiting sense.

CLAIMS:

1. A microcapsule comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being
5 encapsulated by an outer shell.
2. The microcapsule according to claim 1, wherein the outer shell is a matrix of shell material that surrounds the agglomeration to form a foam-like structure.
3. The microcapsule according to claim 2, wherein the
10 shell material comprises gelatine, polyphosphate, polysaccharide, or a mixture thereof.
4. The microcapsule according to claim 2, wherein the shell material comprises gelatine type A, gelatine type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan,
15 pectin, carboxymethylcellulose or a mixture thereof.
5. The microcapsule according to claim 2, wherein the shell material is a complex coacervate.
6. The microcapsule according to claim 2, wherein the shell material is a complex coacervate between gelatine A
20 and one or more of a polymer component selected from the group consisting of gelatine type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin and carboxymethylcellulose.
7. The microcapsule according to claim 2, wherein the
25 shell material is a complex coacervate between gelatine A and polyphosphate.
8. The microcapsule according to claims 3, wherein the shell material further comprises an antioxidant.

9. The microcapsule according to claim 8, wherein the antioxidant is ascorbic acid or a salt thereof.

10. The microcapsule according to claim 8, wherein the antioxidant is sodium ascorbate.

5 11. The microcapsule according to claim 2, wherein the outer shell has an average diameter of from about 1 μm to about 2000 μm .

12. The microcapsule according to claim 2, wherein the outer shell has an average diameter of from about 20 μm to
10 about 1000 μm .

13. The microcapsule according to claim 2, wherein the outer shell has an average diameter of from about 20 μm to about 100 μm .

14. The microcapsule according to claim 2, wherein the
15 outer shell has an average diameter of from about 50 μm to about 100 μm .

15. The microcapsule according to claim 2, wherein the primary shells have an average diameter of from about 40 nm to about 10 μm .

20 16. The microcapsule according to claim 2, wherein the primary shells have an average diameter of from about 0.1 μm to about 5 μm .

17. The microcapsule according to claim 2, wherein the primary shells have an average diameter of about 1 μm .

25 18. The microcapsule according to claim 2 having a payload of loading substance of up to about 70% by weight.

19. The microcapsule according to claim 2, wherein the loading substance is a solid, a liquid or a mixture thereof.

20. The microcapsule according to claim 2, wherein the loading substance is grease, oil or a mixture thereof.

21. The microcapsule according to claim 2, wherein the loading substance is a biologically active substance.

5 22. The microcapsule according to claim 2, wherein the loading substance is a nutritional supplement.

23. The microcapsule according to claim 2, wherein the loading substance is a triglyceride, an omega-3 fatty acid, an ester of an omega-3 fatty acid and/or mixtures thereof.

20 24. The microcapsule according to claim 2, wherein the loading substance is a phytosterol ester of docosaheptaenoic acid and/or eicosapentaenoic acid, a C₁-C₆ alkyl ester of docosaheptaenoic acid and/or eicosapentaenoic acid, and/or a mixture thereof.

25 25. A process for preparing microcapsules, the process comprising:

(a) providing an aqueous mixture of a loading substance, a first polymer component of shell material and a second polymer component of shell material;

30 (b) adjusting pH, temperature, concentration, mixing speed or a combination thereof to form shell material comprising the first and second polymer components, the shell material forming primary shells around the loading substance;

35 (c) cooling the aqueous mixture to a temperature above gel point of the shell material until the primary shells form agglomerations; and,

(d) further cooling the aqueous mixture to form an outer shell of shell material around the agglomerations.

26. The process according to claim 25, wherein the first polymer component is gelatine type A.

27. The process according to claim 25, wherein the second polymer component is gelatine type B, polyphosphate,
5 gum arabic, alginate, chitosan, carrageenan, pectin, carboxymethylcellulose or a mixture thereof.

28. The process according to claim 25, wherein the second polymer component is polyphosphate.

29. The process according to claim 25, wherein the
10 loading substance is grease, oil or a mixture thereof and is dispersed as an emulsion in the aqueous mixture.

30. The process according to claim 25, wherein the loading substance is a triglyceride, an omega-3 fatty acid, an ester of an omega-3 fatty acid and/or mixtures thereof.

31. The process according to claim 25, wherein the
15 loading substance is provided in an amount of from about 1% to about 15% by weight of the aqueous mixture.

32. The process according to claim 25, wherein an antioxidant is added to the aqueous mixture in part (a).

33. The process according to claim 25, wherein
20 ascorbic acid or a salt thereof is added to the aqueous mixture in part (a).

34. The process according to claim 25, wherein sodium ascorbate is added to the aqueous mixture in part (a).

35. The process according to claim 25, wherein the pH
25 is adjusted to a value from 3.5-5.0.

36. The process according claim 25, wherein the pH is adjusted to a value from 4.0-5.0.

37. The process according to claim 25, wherein the temperature is initially from about 40°C to about 60°C.

38. The process according to claim 25, wherein the temperature is initially about 50°C.

5 39. The process according to claim 25, wherein the mixture is cooled at a rate of 1°C/10 minutes.

40. The process according to claim 25, wherein the mixture is cooled until it reaches a temperature of from about 5°C to about 10°C.

10 41. The process according to claim 25, wherein the mixture is cooled until it reaches a temperature of about 5°C.

42. The process according to claim 25, further comprising step (g) adding a cross-linker to cross-link the
15 shell material.

43. The process according to claim 42, wherein the cross-linker is an enzymatic cross-linker, an aldehyde, tannic acid, alum or a mixture thereof.

44. The process according to claim 42, wherein the
20 cross-linker is gluteraldehyde.

45. The process according to claim 42, wherein the cross-linker is transglutaminase.

46. The process according to claim 25, further comprising step of drying the microcapsules.

25 47. A process for preparing microcapsules, the process comprising:

- (a) providing an aqueous mixture of a first polymer component of shell material;
- (b) dispersing a loading substance into the aqueous mixture;
- 5 (c) then adding a second polymer component of shell material to the aqueous mixture;
- (d) adjusting pH, temperature, concentration, mixing speed or a combination thereof to form shell material comprising the first and second polymer components, the
- 10 shell material forming primary shells around the loading substance;
- (e) cooling the aqueous mixture to a temperature above gel point of the shell material until the primary shells form agglomerations; and,
- 15 (f) further cooling the aqueous mixture to form an outer shell of shell material around the agglomerations.
48. The process according to claim 47, wherein the first polymer component is gelatine type A.
49. The process according to claim 47, wherein the
- 20 second polymer component is gelatine type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, carboxymethylcellulose or a mixture thereof.
50. The process according to claim 47, wherein the second polymer component is polyphosphate.
- 25 51. The process according to claim 47, further comprising adding more polymer components to the aqueous mixture in part (e).

52. The process according to claim 47, wherein the loading substance is grease, oil or a mixture thereof and is dispersed as an emulsion in the aqueous mixture.

53. The process according to claim 47, wherein the loading substance is a triglyceride, an omega-3 fatty acid, an ester of an omega-3 fatty acid and/or mixtures thereof.

54. The process according to claim 47, wherein the loading substance is provided in an amount of from about 1% to about 15% by weight of the aqueous mixture.

55. The process according to claim 47, wherein an antioxidant is added to the aqueous mixture in part (a).

56. The process according to claim 47, wherein ascorbic acid or a salt thereof is added to the aqueous mixture in part (a).

57. The process according to claim 47, wherein sodium ascorbate is added to the aqueous mixture in part (a).

58. The process according to claim 47, wherein the pH is adjusted to a value from 3.5-5.0.

59. The process according claim 47, wherein the pH is adjusted to a value from 4.0-5.0.

60. The process according to claim 47, wherein the temperature is initially from about 40°C to about 60°C.

61. The process according to claim 47, wherein the temperature is initially about 50°C.

62. The process according to claim 47, wherein the mixture is cooled at a rate of 1°C/10 minutes.

63. The process according to claim 47, wherein the mixture is cooled until it reaches a temperature of from about 5°C to about 10°C.

64. The process according to claim 47, wherein the
5 mixture is cooled until it reaches a temperature of about 5°C.

65. The process according to claim 47, further comprising step (g) adding a cross-linker to cross-link the shell material.

10 66. The process according to claim 65, wherein the cross-linker is an enzymatic cross-linker, an aldehyde, tannic acid, alum or a mixture thereof.

67. The process according to claim 65, wherein the cross-linker is gluteraldehyde.

15 68. The process according to claim 65, wherein the cross-linker is transglutaminase.

69. The process according to claim 47, further comprising step of drying the microcapsules.

70. Microcapsules prepared by a process according to
20 claim 25.

71. Microcapsules prepared by a process according to claim 47.

1/1



Fig. 1




Fig. 2

INTERNATIONAL SEARCH REPORT

Internat I Application No

PCT/CA 03/00520

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A23L1/00 A23P1/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A23P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 051 304 A (DAVID JACKY ET AL) 24 September 1991 (1991-09-24)</p> <p>column 2, paragraph 3 - paragraph 6 column 4, paragraph 1 - column 5, paragraph 2 column 5; example 1 column 6; example 4</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-6, 11-14, 19-23, 25-30, 35-38, 40, 42-44, 46-49, 52, 53, 58-60, 63, 65-67, 69-71</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

21 July 2003

Date of mailing of the international search report

05/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Inceisa, L

INTERNATIONAL SEARCH REPORT

Internat I Application No

PCT/CA 03/00520

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 6 325 951 B1 (SOPER JON C ET AL) 4 December 2001 (2001-12-04)</p> <p>the whole document figures 1-4</p>	<p>1-7, 11-14, 19-23, 25-30, 35-38, 40-45, 70,71</p>
X	<p>US 4 222 891 A (OKIMOTO TOMOYUKI ET AL) 16 September 1980 (1980-09-16) cited in the application</p> <p>column 3, line 35 - line 56 column 4, line 45 -column 5, line 58 column 8 -column 9; examples 1-10</p>	<p>1-6, 11-17, 20-23, 25, 35-37, 40, 42-44, 46-49, 51,53, 58-60, 63, 65-67, 69-71</p>
X	<p>US 5 780 056 A (AKAMATSU TAKU ET AL) 14 July 1998 (1998-07-14) cited in the application column 2, paragraphs 1-5 column 4, paragraph 6 - paragraph 7 column 6 - column 7, example column 7; example 1 column 9 -column 10; table 1</p>	<p>1-4,8,9, 11-17, 19-23</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/CA 03/00520

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5051304	A	24-09-1991	FR	2608456 A1	24-06-1988
			CA	1323307 C	19-10-1993
			EP	0273823 A1	06-07-1988
			JP	63197540 A	16-08-1988
			PT	86390 A , B	01-01-1988
US 6325951	B1	04-12-2001	US	6039901 A	21-03-2000
			AU	5284198 A	06-08-1998
			BR	9800513 A	25-05-1999
			CA	2228165 A1	31-07-1998
			EP	0856355 A2	05-08-1998
			JP	10249184 A	22-09-1998
			SG	75823 A1	24-10-2000
			ZA	9800585 A	31-07-1998
US 4222891	A	16-09-1980	JP	1373398 C	07-04-1987
			JP	54032178 A	09-03-1979
			JP	61040456 B	09-09-1986
			JP	54074282 A	14-06-1979
			AU	514205 B2	29-01-1981
			AU	3281978 A	02-08-1979
			DE	2803687 A1	03-08-1978
			ES	466986 A1	16-10-1978
			FR	2378561 A1	25-08-1978
			GB	1567426 A	14-05-1980
US 5780056	A	14-07-1998	JP	9302379 A	25-11-1997

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.